CD19 and non-Hodgkin lymphoma: Recent work utilized a retrospective review of patients with non-Hodgkin lymphoma (NHL) or acute lymphocytic leukemia (ALL) treated with CD19 CAR T-cells and found that the administration of broad spectrum antibiotics within four weeks prior to the first treatment was strongly associated with shorter overall survival and increased incidence of ICANS [13].